This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
03/30/15 - 11:51:51 AM ET (BATS BZX Real-time Price)
Div Yield: --
HEB Day's Range
HEB 52 Week Range
HEB Business Summary
Hemispherx Biopharma, Inc., a specialty pharmaceutical company, is engaged in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States.View HEB key stats
Hemispherx Biopharma Inc - HEB - EQUITY
Reviewed By: TheStreet Ratings on .
Report Summary: TheStreet Ratings team rates Hemispherx Biopharma Inc as a
Sell with a ratings score of D.
Report Snippet: We rate Hemispherx Biopharma Inc (HEB) a Sell.
This is based on the convergence of positive investment measures, which should help this stock outperform the majority
of stocks that we rate. The company's strengths can be seen in multiple areas, such as its solid stock price performance,
growth in earnings per share, revenue growth, notable return on equity and expanding profit margins. Although the company
may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.